📢 Breaking News!
The NMPA has conditionally approved #Lisaftoclax Tablets 💊—an innovative drug by Suzhou Ascentage Pharma Company Limited.

📎 Learn more: dengyuemed.com/product/asce...

📧 info@dengyuemed.com
#AscentagePharma #NMPAApproval #CLL #SLL #BTKInhibitor
#HongKongDengYueMedicine

ASH 2024 Highlights Ascentage Pharma's Promising Clinical Data on Lisaftoclax for Relapsed/Refractory Multiple Myeloma Ascentage Pharma showcased encouraging outcomes from its Bcl-2 inhibitor, lisaftoclax, at ASH 2024, indicating significant potential for treating relapsed/refractory multiple myeloma patients.

ASH 2024 Highlights Ascentage Pharma's Promising Clinical Data on Lisaftoclax for Relapsed/Refractory Multiple Myeloma #USA #San_Diego #Ascentage_Pharma #Multiple_Myeloma #Lisaftoclax

ASH 2024: Ascentage Pharma Unveils Promising Findings for Lisaftoclax in Myelodysplastic Syndrome Treatment Ascentage Pharma recently shared new clinical data for its Bcl-2 inhibitor, Lisaftoclax, at ASH 2024, showcasing significant potential in treating myelodysplastic syndrome while ensuring safety for patients.

ASH 2024: Ascentage Pharma Unveils Promising Findings for Lisaftoclax in Myelodysplastic Syndrome Treatment #USA #San_Diego #Ascentage_Pharma #MDS #Lisaftoclax

Potential of Ascentage Pharma's Lisaftoclax in Treating CLL/SLL Showcased at ASH 2024 At ASH 2024, Ascentage Pharma unveiled promising clinical data for Lisaftoclax, a Bcl-2 inhibitor, showing effectiveness in CLL patients previously treated with Venetoclax.

Potential of Ascentage Pharma's Lisaftoclax in Treating CLL/SLL Showcased at ASH 2024 #USA #San_Diego #Ascentage_Pharma #Lisaftoclax #CLL_Treatment

ASH 2024 Reveals Promising Results for Olverembatinib and Lisaftoclax in Treating Pediatric Leukemia At ASH 2024, Ascentage Pharma presented data showing the combination of olverembatinib and lisaftoclax could be an effective chemotherapy-free treatment for R/R Ph+ ALL in children.

ASH 2024 Reveals Promising Results for Olverembatinib and Lisaftoclax in Treating Pediatric Leukemia #USA #San_Diego #Olverembatinib #Ascentage_Pharma #Lisaftoclax